Triumph Capital Management
IONS icon

Triumph Capital Management’s Ionis Pharmaceuticals IONS Stock Holding History

Triumph Capital Management’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$2.23K Hold
50
– – ﹤0.01% 1589
2026
Q2 		$3.96K Hold
50
– – ﹤0.01% 1428
2026
Q1 		$3.75K Hold
50
– – ﹤0.01% 1400
2025
Q4 		$3.96K Buy
+50
New +$3.76K ﹤0.01% 1327

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 42.55% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $123B AUM 30.05% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Tweedy, Browne Co
Tweedy, Browne Co Stamford, Connecticut $1.23B AUM 16.54% 1-Year Est. Return

Triumph Capital Management's IONS Position: Q3 2026 in Review

Triumph Capital Management held its Ionis Pharmaceuticals (IONS) position steady in Q3 2026 at 50 shares worth $2.23K. The position accounts for ﹤0.01% of the portfolio, ranked #1589.

Triumph Capital Management first reported a position in IONS in Q4 2025 and has held it in 4 quarters since. The position peaked at $3.96K in Q2 2026. 321 funds tracked by Wall St. Rank hold IONS as of Q3 2026.

  • Triumph Capital Management held 50 shares of Ionis Pharmaceuticals worth $2.23K as of Q3 2026.
  • Triumph Capital Management left its Ionis Pharmaceuticals share count unchanged in Q3 2026.
  • Ionis Pharmaceuticals made up ﹤0.01% of Triumph Capital Management's portfolio in Q3 2026, its #1589 holding.
  • Triumph Capital Management first reported a position in Ionis Pharmaceuticals in Q4 2025 and has held it in 4 quarters since.
  • Triumph Capital Management's Ionis Pharmaceuticals position peaked at $3.96K in Q2 2026.
  • 321 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q3 2026.

Based on Triumph Capital Management's 13F filing for Q3 2026, filed 14 Oct 2026.